The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic
Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains. (Source: Bloomberg)
This is a summary aggregated from Bloomberg Markets. Read the complete article on the original site:
Read full article at Bloomberg Markets
